As part of our ongoing commitment to building a greener and more responsible future, we are happy to announce the completion of the installation of 540 solar panels in one of our facilities. This action reinforces our dedication to sustainability and aligns with the Sustainable Development Goals (SDGs) outlined in the 2030 Agenda.
What does this mean for the environment?
With this installation, we are making a significant contribution to the environment by:
- Reducing our CO2 emissions by 130 tons annually, equivalent to the amount absorbed by over 6,000 trees.
- Achieving energy efficiency improvements of 18% to 30%, allowing us to use resources more responsibly.
- Generating clean, renewable energy, enough to power approximately 150 homes per year.
A commitment to positive change
This solar energy installation, with a capacity of 313.2 kWp, not only represents a significant reduction in our carbon footprint but also reaffirms our commitment to transforming our operations into a source of clean and sustainable energy. We have covered 1500 m² of our space with solar panels, marking a significant step in the fight against climate change.
Our commitment to sustainability does not stop here. We aim at driving projects for a brighter future where technology and respect for the environment go hand in hand. This is just the beginning of a series of initiatives that align our operations with sustainability and social responsibility principles.
Together, we are moving toward a greener, cleaner future for all!
News
October 01, 2024
We are moving towards a more sustainable future with solar energy!
Explore more
Insights
Advanced Therapies Conference Recap: Key Takeaways from Key CGT Fall Conferences
Our scientific and business teams at Viralgen have been crisscrossing the globe to get insights on our peers’ latest advances in cell and gene therapy – and to share our own. Here’s a quick rundown of what we heard during three key conferences in...
READ MORE
November 05, 2025
Resources
Webinar: What Comes Next? Industry Takeaways from FDA’s Cell and Gene Therapy Listening Session
The US Food and Drug Administration’s Office of Therapeutic Products (OTP) convened a public listening session on September 18, 2025, asking the cell and gene therapy (CGT) community how prior knowledge can be leveraged to accelerate the development...
READ MORE
October 17, 2025
Resources
Webinar: Making a meaningful impact in AAV
In October, Andy Holt, Chief Commercial Officer at Viralgen, provided attendees of Meeting on the Mesa 2025 with an update on three of the company’s latest initiatives to help innovators advance their gene therapies more efficiently: Plasmid...
READ MORE
October 17, 2025